BIODEGRADABLE OCULAR IMPLANT

• US 20130209538A1
• Filed: 08/12/2011
• Published: 08/15/2013
• Est. Priority Date: 08/12/2010
• Status: Abandoned Application

• Current Assignee: Singapore Health Services Pte Limited (MOH Holdings Pte Limited), Nanyang Technological University
• Original Assignee: Singapore Health Services Pte Limited (MOH Holdings Pte Limited), Nanyang Technological University
• Inventors: Venkatraman, Subramanian, Boey, Yin Chiang Freddy, Wong, Tina, Metha, Jodhbh
• Application Number:
  US13/816,637
• Publication Number:
  US 20130209538A1
• Time in Patent Office: Days
• US Class Current: 424/428
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/125 having a macromolecular matrix
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: B05D 5/00 Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
• CPC Class Codes: B29C 39/02 for making articles of definite length, i.e. discrete articles
• CPC Class Codes: B29C 39/025 for making multilayered articles
• CPC Class Codes: B29D 11/023 Implants for natural eyes
• CPC Class Codes: B29K 2067/04 Polyesters derived from hydroxycarboxylic acids
• CPC Class Codes: B29K 2067/046 PLA, i.e. polylactic acid or polylactide
• CPC Class Codes: B29K 2105/0035 Medical or pharmaceutical agents
• CPC Class Codes: B29K 2105/0073 : Solution
• CPC Class Codes: B29K 2995/0056 : Biocompatible, e.g. biopolymers or bioelastomers
• CPC Class Codes: B29K 2995/006 : Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C08L 69/005 : Polyester-carbonates

Abstract

The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Claims

1. A biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein.

2. The biodegradable ocular implant of claim 1, further comprising at least one top layer comprising a second biodegradable polymer, wherein the at least one top layer is arranged on top of the first layer.

3. The biodegradable ocular implant of claim 2, further comprising at least one bottom layer comprising a third biodegradable polymer, wherein the first layer is arranged on top of the at least one bottom layer to thereby form a sandwich assembly having the first layer arranged between the at least one top layer and the at least one bottom layer.

4. The biodegradable ocular implant of any one of claims 1-3, wherein the at least one top layer, or the at least one bottom layer, or both, contains a drug dispersed or dissolved in the respective layer.

5. The biodegradable ocular implant of any one of claims 1-4, wherein the drug is uniformly dissolved in the polymer matrix of the respective layer.

6. The biodegradable ocular implant of any one of claims 1-4, wherein the drug is dispersed at the surface of the respective layer.

7. The biodegradable ocular implant of any one of claims 2-6, wherein the first biodegradable polymer, the second biodegradable polymer, and the third biodegradable polymer are the same.

8. The biodegradable ocular implant of any one of claims 2-6, wherein the first biodegradable polymer, the second biodegradable polymer, and the third biodegradable polymer are different.

9. The biodegradable ocular implant of any one of claims 1-8, wherein each biodegradable polymer is independently selected from the group consisting of polylactide (PLA), poly-L-lactide (PLLA), poly-D-lactide (PDLA), poly(L-lactide-co-glycolide) (PLGA), polyethylene glycol (PEG), polypropylene glycol (PPG), polycaprolactone (PCL), polyesteramide (PEA), a PLLA copolymer, a PLGA copolymer, a PDLA copolymer, a PCL copolymer, a PEA copolymer, a PEG copolymer, a PPG copolymer, and mixtures thereof.

10. The biodegradable ocular implant of claim 9, wherein the biodegradable polymer is a copolymer of PLA and PCL.

11. The biodegradable ocular implant of claim 10, wherein the molar ratio PLA:

PCL is between about 90;

10 and about 10;

90.

12. The biodegradable ocular implant of claim 11, wherein the molar ratio PLA:

PCL is 70;

30.

13. The biodegradable ocular implant of claim 9, wherein the biodegradable polymer is a triblock copolymer comprising PLA as end-blocks and a middle block selected from the group consisting of PCL, a copolymer of PCL and trimethylene carbonate (TMC), a copolymer of PCL and PLGA.

14. The biodegradable ocular implant of claim 9, wherein the biodegradable polymer is a multiblock copolymer of polylactide-caprolactone (PLC) and PLA.

15. The biodegradable ocular implant of claim 9, wherein the biodegradable polymer is a polyurethane type copolymer formed from di-isocyanates and butanediol, and soft segments selected from PCL/PLA and PCL/TMC.

16. The biodegradable ocular implant of any one of claims 2-15, wherein the at least one top layer or the at least one bottom layer is impermeable for the drug to provide for a directional release of the drug.

17. The biodegradable ocular implant of any one of claims 1-16, wherein each of the biodegradable polymers of the different layers has a different degradation rate.

18. The biodegradable ocular implant of any one of claims 1-17, wherein the drug comprises an ocular drug.

19. The biodegradable ocular implant of any one of claims 1-18, wherein the drug is selected from the group consisting of an immunosuppressant agent, an antibiotic, an anti-inflammatory agent, an anti-scarring agent, an anti-glaucoma medication, a prostaglandin analogue, an anti-steroidal agents, an antimicrobial agent, an anti-fibrotic antibody, and a small interfering ribonucleic acid (siRNA) molecule against fibrosis.

20. The biodegradable ocular implant of claim 19, wherein the drug is betamethasone, prednisolone, dexmethasone, cyclosporine, latanoprost and derivates, timolol maleate, valproic acid, or ciproflaxin.

21. The biodegradable ocular implant of any one of claims 1-20, wherein each respective layer comprises 70-98 wt % (based on total weight of the layer) of the polymer matrix and 2-30 wt % of the drug.

22. The biodegradable ocular implant of any one of claims 1-21, wherein the modulus of the implant is between about 0.1 MPa and about 1,000 MPa.

23. The biodegradable ocular implant of any one of claims 1-22, wherein the elongation-to-break point of the implant is at least 300%.

24. The biodegradable ocular implant of any one of claims 1-23, further comprising an excipient or plasticizer.

25. The biodegradable ocular implant of claim 24, wherein the excipient or plasticizer is PEG, triethyl citrate (TEC) or glycerol.

26. The biodegradable ocular implant of any one of claims 1-25, wherein the implant is formable to a desired shape.

27. The biodegradable ocular implant of claim 26, wherein the desired shape comprises a curved shape or a convex shape.

28. The biodegradable ocular implant of claim 26 or 27, wherein the desired shape is formable after insertion into an eye of a subject.

29. The biodegradable ocular implant of any one of claims 26-28, wherein the desired shape is formed by exposing the implant to a temperature of about 37°

C.

30. The biodegradable ocular implant of any one of claims 1-29, wherein each of the layers has a thickness of about 0.1 micron to about 10 microns.

31. The biodegradable ocular implant of any one of claims 1-30, wherein the implant has an overall thickness of about 1 mm to about 2 mm.

45. A method for treating an ocular disease or reducing preoperative effects of multiple quadrant corneal vascularization or improving corneal graft survival, comprising implanting the biodegradable ocular implant of any one of claims 1-31 to a subject in need thereof.

46. The method of claim 45, wherein the ocular disease is an ocular surface disease selected from the group consisting of vernal keratoconjunctivits and allergic eye disease.

32. A method of forming a biodegradable ocular implant for sustained drug delivery, comprising:

(a) providing a first layer comprising a first biodegradable polymer; and

(b) loading the first biodegradable polymer with a drug.

33. The method of claim 32, wherein providing the first layer comprises:

(a) dissolving the first biodegradable polymer in a suitable solvent to form a first solution; and

(b) evaporating the solvent to obtain the first layer.

34. The method of claim 33, wherein loading comprises adding the drug to the first solution prior to evaporating the solvent.

35. The method of claim 32, wherein loading comprises immersing the first layer in a solution containing the drug.

36. The method of claim 33, wherein loading comprises simultaneously dissolving the drug and the first biodegradable polymer in the solvent prior to evaporating the solvent.

37. The method of any one of claims 32-36, further comprising:

(a) dissolving a second biodegradable polymer with a suitable solvent to form a second solution;

(b) casting the second solution on top of the first layer; and

(c) evaporating the solvent to form a top layer.

38. The method of any one of claims 32-37, further comprises forming a bottom layer on which the first layer is arranged, comprising:

(a) dissolving a third biodegradable polymer with a suitable solvent to form a third solution;

(b) evaporating the solvent to form a bottom layer; and

(b) depositing the first layer on top of the bottom layer.

39. The method of any one of claims 32-38, wherein the first layer, or the top layer, or the bottom layer is formed over a curved-surfaced member.

40. The method of claim 39, wherein the curved-surfaced member comprises a tubular scaffold or a cylinder.

41. The method of claim 39 or 40, further comprising cutting the respective layer radially to obtain a convex shape.

42. The method of any one of claims 33-38, wherein the first layer, or the top layer, or the bottom layer is casted into a convex mold to obtain a convex shape.

43. The method of any one of claims 33-38, wherein the first layer, or the top layer, or the bottom layer is casted into a flat sheet, followed by heat-shaping the flat sheet into a convex shape.

44. The method of claim 43, wherein the implant comprises an outermost layer and wherein the heat-shaping step is applied to the outermost layer at its glass transition temperature (Tg).

47. Use of a biodegradable ocular implant for the treatment of an ocular disease or reducing preoperative effects of multiple quadrant corneal vascularization or improving corneal graft survival.

48. A biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer matrix capable of containing a drug dispersed therein.

49. A multi-layered biodegradable ocular implant for sustained drug delivery, comprising:

(a) a first layer comprising a first biodegradable polymer capable of containing a drug dispersed therein; and

(b) at least one other layer comprising a second biodegradable polymer arranged adjacent the first layer.

50. The multi-layered biodegradable ocular implant of claim 49, wherein the second biodegradable polymer is capable of containing a drug dispersed therein.